{'fraction_non_alphanumeric': 0.027149321266968326, 'fraction_numerical': 0.0, 'mean_word_length': 7.512820512820513, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Liposome‐encapsulated dexamethasone attenuates ventilator‐induced lung inflammation

BACKGROUND AND PURPOSE Systemic glucocorticoid therapy may effectively attenuate lung inflammation but also induce severe side‐effects. Delivery of glucocorticoids by liposomes could therefore be beneficial. We investigated if liposome‐encapsulated dexamethasone inhibited ventilator‐induced lung inflammation. Furthermore, we evaluated whether targeting of cellular Fcγ‐receptors (FcγRs) by conjugating immunoglobulin G (IgG) to liposomes, would improve the efficacy of dexamethasone‐liposomes in attenuating granulocyte infiltration, one of the hallmarks of lung inflammation.